QR Pharma, Inc. announced the appointment of four world-class key opinion leaders to its Scientific Advisory Board (SAB). These new appointments join QR Pharma's previous roster of impressive advisors in order to provide strategic leadership and direction to support the development of the breakthrough mechanism of action of Posiphen in neurodegenerative disease. The four new scientific advisory board members are: William Mobley, M.D., Ph.D., is Distinguished Professor, Department of Neurosciences Florence Riford Chair for Alzheimer Research and Associate Dean for Neurosciences Initiatives. He is a member of the National Academy of Medicine. Gregory Petsko, Ph.D., is the Arthur J. Mahon Professor of Neurology and Neuroscience and Director, Helen and Robert Appel Alzheimer'sDisease Research Institute at Weill Cornell Medical College and adjunct professor of Biomedical Engineering at Cornell University. He is a member of the National Academy of Sciences. Sidney Strickland, Ph.D., is the Vice President and Dean for Educational Affairs and Research Professor, Patricia and John Rosenwald Laboratory of Neurobiology and Genetics at Rockefeller University. Rudolph Tanzi, Ph.D., is Vice-Chair and Director of Neurology, Genetics and Aging, and the Joseph and Rose Kennedy Professor of Neurology at Massachusetts General Hospital. Jeffrey Cummings, MD, Cleveland Clinic, is Director, Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio. Camille and Larry Ruvo Chair of the Neurological Institute of Cleveland Clinic and Professor of Medicine (Neurology), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Peter Davies, PhD, is Director of the Litwin-Zucker Research Center for the Study of Alzheimer's Disease, The Feinstein Institute for Medical Research and Professor, Pathology and Neuroscience, at the Hofstra Northwell School of Medicine atHofstra University.